Song I H, Rudwaleit M, Listing J, Sieper J
Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany.
Ann Rheum Dis. 2009 Nov;68(11):1701-7. doi: 10.1136/ard.2008.099226. Epub 2008 Nov 24.
To compare the original Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with a modified BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with ankylosing spondylitis (AS) without peripheral manifestations.
The mini-BASDAI was calculated by omitting questions 3 and 4. The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with non-steroidal anti-inflammatory drugs and tumour necrosis factor alpha inhibitors. Sensitivity to change was assessed by calculating effect sizes.
Up to 70% of AS patients did not have peripheral involvement. Patients with peripheral involvement had higher disease activity in all activity parameters. The mini-BASDAI had higher values compared with the original BASDAI, also in the subgroup with peripheral manifestations. However, the mini-BASDAI did not correlate better with other markers of disease activity compared with the original BASDAI. Furthermore, effect sizes of the original BASDAI and mini-BASDAI were comparable in the treatment trials. Interestingly, approximately 5% of active AS patients with pure axial disease manifestation were identified whose disease activity was underestimated by the original BASDAI.
On a group level using the mini-BASDAI did not result in an advantage to assess disease activity or in the subgroup without peripheral involvement. In only approximately 5% of AS patients was the mini-BASDAI superior to the original BASDAI.
比较原始的巴斯强直性脊柱炎疾病活动指数(BASDAI)与一种改良的BASDAI(不包含关于外周关节炎的问题3和附着点炎的问题4,以下称为迷你BASDAI),作为评估无外周表现的强直性脊柱炎(AS)患者疾病活动度的工具。
通过省略问题3和4来计算迷你BASDAI。在来自三个AS队列的总共692例患者中评估原始BASDAI和迷你BASDAI与患者整体及其他疾病参数的相关性,其中包括一个观察性AS队列以及两个接受非甾体抗炎药和肿瘤坏死因子α抑制剂治疗的临床试验人群。通过计算效应量来评估对变化的敏感性。
高达70%的AS患者无外周受累。有外周受累的患者在所有活动参数方面疾病活动度更高。与原始BASDAI相比,迷你BASDAI的值更高,在外周表现亚组中也是如此。然而,与原始BASDAI相比,迷你BASDAI与疾病活动的其他标志物的相关性并未更好。此外,在治疗试验中,原始BASDAI和迷你BASDAI的效应量相当。有趣的是,约5%有单纯轴向疾病表现的活动性AS患者被发现其疾病活动度被原始BASDAI低估。
在组水平上,使用迷你BASDAI在评估疾病活动度方面并无优势,在无外周受累的亚组中也是如此。仅约5%的AS患者中,迷你BASDAI优于原始BASDAI。